Oral Oncology
Volume 46, Issue 3 , Pages 172-177, March 2010

Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib☆

Centre Antoine-Lacassagne, Nice, France

Received 25 August 2009; received in revised form 20 November 2009; accepted 23 November 2009. published online 16 February 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Results presented in part during the 2008 annual meeting of the American Association for Cancer Research (AACR).

PII: S1368-8375(09)00979-8

doi:10.1016/j.oraloncology.2009.11.010

Oral Oncology
Volume 46, Issue 3 , Pages 172-177, March 2010

Article Tools

* Image Usage & Resolution